ArticlePerspectives in clinical research
Is drug development in India is responsive to disease burden: A descriptive study.
Article in Perspectives in clinical research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to investigate the association between approved drugs and disease burden in India and to assess the need to address the unmet healthcare needs of the public. Materials and Methods: This descriptive study was conducted using two sets of data. The data on new drug approvals from January 2020 to August 2024 were downloaded from the Central Drugs Standard Control Organization website in India, and data on disease burden (mortality and disability) from 2017 to 2021 were downloaded from the World Health Organization website. The relationship between drug approval and disease burden was assessed using descriptive analysis. Results: From 2020 to 2024, a total of 126 new drugs were approved; of these 29.36% were approved for the leading causes of mortality and morbidity. Ischemic heart disease, chronic obstructive pulmonary disease, diabetes, diarrheal diseases, lower respiratory tract infection, and tuberculosis were among the leading causes of mortality and morbidity. A total of 19 (15%) drugs were approved for infectious diseases, including 9 (7%) for COVID-19. Other drugs approved included only 9 (7%) for cardiovascular disease, 8 (6%) for diabetes, and 1 (0.7%) for anemia. Conclusion: Our study found that although new drug development in India is increasingly focused on addressing the country's evolving disease burden of noncommunicable diseases and infectious diseases, a lower proportion of new drugs is being approved for the leading cause of morbidity and mortality. There is a need to intensify research output, as significant potential exists for improvement in drug development in India to address this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.